190 patents
Page 5 of 10
Utility
Masked Antibody Formulations
28 Jul 22
Formulations comprising masked antibodies are provided.
Danielle Leiske, Elise Cunningham, Shan Jiang, Lori Westendorf, Michael Feldhaus, Eoin Francis James Cosgrave, Catherine Marie Eakin
Filed: 4 Jun 20
Utility
Methods of Reducing Side Effects of ANTI-CD30 Antibody Drug Conjugate Therapy
21 Jul 22
The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy.
Thomas Manley, Neil Josephson
Filed: 1 Nov 18
Utility
Conjugates of Quaternized Tubulysin Compounds
21 Jul 22
Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action.
Patrick J. BURKE, Joel COURTER
Filed: 22 Nov 21
Utility
Process for the preparation of tubulysins and intermediates thereof
19 Jul 22
Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.
Kun-Liang Wu, Qingwu Jin, Wendel Doubleday
Filed: 7 Sep 18
Utility
Methods of Treating Breast Cancer with Tucatinib
23 Jun 22
The invention provides tucatinib and its use in methods of treating cancer, such as breast cancer.
Luke WALKER, Christopher J. ENDRES, Anthony Jaeyong LEE, Hao SUN, Ariel R. TOPLETZ-ERICKSON
Filed: 24 Jan 20
Utility
Camptothecin Peptide Conjugates
23 Jun 22
Provided herein are Camptothecin Conjugates, Camptothecin-Linker Compounds, Camptothecin Compounds, intermediates thereof, and method of preparing the same.
Scott JEFFREY, Ryan Lyski, Maureen Ryan, Julia Cochran
Filed: 27 Oct 21
Utility
Detection and treatment of CD30
21 Jun 22
The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
Tina Albertson, Maria L. Smith
Filed: 13 Sep 19
Utility
Cysteine Mutated Antibodies for Conjugation
9 Jun 22
The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering.
Andrew WAIGHT, Chris LEISKE, Travis BIECHELE, Django SUSSMAN, Patrick BURKE, Jocelyn LEISKE
Filed: 28 Feb 18
Utility
Pharmaceutical Compositions Comprising ANTI-191P4D12 Antibody Drug Conjugates and Methods of Use Thereof
9 Jun 22
A pharmaceutical composition comprising an antibody drug conjugate comprising an antibody or antigen binding fragment thereof that binds to 191P4D12 conjugated to one or more units of monomethyl auristatin E (MMAE) and a pharmaceutically acceptable excipient comprising L-histidine, polysorbate-20 (TWEEN-20), and at least one of trehalose dihydrate and sucrose.
Orla MCGARVEY, Gayathri RATNASWAMY, Yingqing SUN, Marie Rose VAN SCHRAVENDIJK
Filed: 15 Oct 19
Utility
Anti-NTB-A antibodies and related compositions and methods
7 Jun 22
Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A.
Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
Filed: 30 Jun 16
Utility
Treatment of HER2 Positive Cancers
2 Jun 22
In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject.
Scott Peterson, Luke Walker
Filed: 18 Nov 21
Utility
CD19 binding agents and uses thereof
17 May 22
This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.
Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
Filed: 14 Feb 18
Utility
Beta-glucuronide-linker Drug Conjugates
12 May 22
Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.
Scott JEFFREY
Filed: 15 Jun 21
Utility
Combination therapy using a LIV1-ADC and a chemotherapeutic
10 May 22
The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
Django Sussman, Fu Li, Ana Kostic
Filed: 15 Mar 17
Utility
CD47 Antibodies and Uses Thereof for Treating Cancer
5 May 22
Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided.
Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
Filed: 20 Oct 21
Utility
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
3 May 22
The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
Filed: 16 May 19
Utility
Humanized ANTI-LIV1 Antibodies for the Treatment of Cancer
14 Apr 22
Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, as well as for the treatment of cancers, such as, e.g., prostate cancer and melanoma, are provided.
Matt ONSUM, Hailing LU, Zejing WANG
Filed: 27 Sep 21
Utility
Controlled Fucosylation of Antibodies
17 Mar 22
The invention provides methods for preparing antibodies and antibody derivatives with controlled levels of core fucosylation.
Shanta BODDAPATI, Aaron CHEN, Swapnil BHARGAVA
Filed: 18 Dec 19
Utility
Pegylated Drug-linkers for Improved Ligand-drug Conjugate Pharmacokinetics
10 Mar 22
The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit.
Robert LYON, Patrick BURKE, Joshua HUNTER
Filed: 16 Jul 21
Reissue
Humanized antibodies to LIV-1 and use of same to treat cancer
8 Mar 22
The invention provides humanized antibodies that specifically bind to LIV-1.
Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
Filed: 4 Jan 18